Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Imagine wading through severe depression for years, taking medication after medication, with no relief. Now, envision discovering that what you were facing was not major depression but bipolar ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

Dr. Harold Koenig answers the question: 'What Is Depression?' — -- Question: What is the difference between depression and manic depression (bipolar disorder)? Answer: Depression and manic ...

Dr. Roy Perlis answers the question: 'Bipolar Disorder & 'Regular' Depression?' — -- Question: How is bipolar disorder different from unipolar depression or 'regular' depression? Answer: Both ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

The number of South Koreans diagnosed with depression and bipolar disorder each increased nearly 1.5-fold over the past six ...

The number of people suffering from depression or bipolar disorders in Korea has surged, with cases of each of the conditions ...